Jun 10, 2020
Aptevo Therapeutics and Alligator Bioscience Present new Preclinical Data for ALG.APV-527 at the PEGS Virtual Interactive Global Summit
Oct 26, 2019
Adagene Presents Its Lead Antibody Program, ADG106, at International Conferences
Jun 18, 2019
Alligator Bioscience Submits Clinical Trial Application for ATOR-1017
Mar 18, 2019
Alligator Bioscience: New Preclinical Data Demonstrate Strong Anti-tumor Effects for the 4-1BB Antibody ATOR-1017
Feb 19, 2019
Inhibrx Announces Dosing of First Patient in Phase 1 Dose-Escalation Study of INBRX-105, a Novel Multispecific PD-L1 and 4-1BB Antibody
Nov 13, 2018
BioInvent Announces Publication of Data in Leading Cancer Journal Immunity
Nov 09, 2018
Alligator Bioscience and Aptevo Therapeutics Present New Preclinical Data for ALG.APV-527 at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting
Nov 06, 2018
Agenus to Present Data on Neoantigen Vaccines and anti-CD137 Antibody at SITC 2018
Oct 31, 2018
Adagene Announces First Patient Dosed in United States and Acceptance of IND in China for ADG-106
Oct 05, 2018
Alligator Bioscience Receives Government Research Grant
Sep 28, 2018
New Preclinical Data Support Good Tolerability Properties for the 4-1BB Antibody ATOR-1017
Jul 09, 2018
US FDA Approves Adagene IO program IND for Solid Tumor and Non-Hodgkin Lympoma Ph1 trial
Jun 21, 2018
Alligator Bioscience's ATOR-1017 Strongly Activates Both T cells and NK Cells, Important for the Effective Eradication of Tumor Cells
Nov 06, 2017
Eutilex and Huahai Enter Immuno-Oncology Partnership
Sep 13, 2017
Alligator Bioscience Signs Immunotherapy Research Collaboration Agreement for 4-1BB
Jun 13, 2017
TCR(2) Therapeutics Presents Positive Solid Tumor Data for its Novel TRuC(TM) Engineered T Cell Therapies at the World Preclinical Congress